Haleon Buys Back Shares for £9.85M
Ticker: HLNCF · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1900304
Sentiment: bullish
Topics: share-repurchase, insider-activity, company-news
Related Tickers: HLN
TL;DR
Haleon just bought back 1.2M shares for nearly £10M. Bullish.
AI Summary
Haleon plc announced on September 4, 2025, that it repurchased 1,200,000 of its own ordinary shares at an average price of £8.2096 per share. The total cost of these repurchases amounted to £9,851,520. These shares were bought on the London Stock Exchange.
Why It Matters
This share buyback indicates the company's confidence in its valuation and can potentially increase earnings per share for remaining shareholders.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share repurchases, which is a common corporate action.
Key Numbers
- £9.85M — Share Repurchase Cost (Total amount spent by Haleon on buying back its own shares.)
- 1.2M — Shares Repurchased (The volume of Haleon's ordinary shares bought back.)
Key Players & Entities
- Haleon plc (company) — Registrant
- £9,851,520 (dollar_amount) — Total cost of share repurchases
- 1,200,000 (dollar_amount) — Number of shares repurchased
- £8.2096 (dollar_amount) — Average price per share
- September 4, 2025 (date) — Date of transaction
- London Stock Exchange (company) — Exchange where shares were repurchased
FAQ
What was the total number of Haleon plc ordinary shares repurchased on September 4, 2025?
Haleon plc repurchased 1,200,000 ordinary shares.
What was the total amount spent on the share repurchase by Haleon plc?
The total cost of the share repurchases was £9,851,520.
On which stock exchange did Haleon plc conduct these share repurchases?
The repurchases were conducted on the London Stock Exchange.
What was the average price per share paid by Haleon plc for the repurchased shares?
The average price per share was £8.2096.
What is the filing date and report period for this Form 6-K?
The filing date and the conformed period of report is September 4, 2025.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-04 06:43:48
Filing Documents
- a9243x.htm (6-K) — 32KB
- a9243x000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010382.txt ( ) — 38KB
From the Filing
IN OWN SHARES a9243x UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 04 September 2025 - “Transaction in Own Shares”         99.1   Haleon plc:   Transaction in own shares   04 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 354,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 03 September 2025 03 September 2025 03 September 2025 Number of Shares purchased: 354,000 - - Highest price paid per Share (p): 370.3000 - - Lowest price paid per Share (p): 363.4000 - - Volume weighted average price paid per Share (p): 366.1277 - -   Following the settlement of the above, the Company's registered share capital   is 8,955,967,411 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,952,087,206 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/9239X_1-2025-9-3.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:  corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .    SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 04, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary